Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quan-Quan Tan

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Journal of International Medical Research|December 16, 2025
Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulationKe-Jun Liu, Tao Jiang, Quan-Quan Tan, et al.
Cancer Medicine|February 4, 2026
Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 RearrangementQuan-Quan Tan, Yu-Qing Chen, Yu-Er Gao, et al.
Cancer Treatment and Research Communications|April 30, 2023
Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangementQing-Yun Gao, Fa-Man Xiao, Xiao-Cheng Lin, et al.
Discover Oncology|May 27, 2026
Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skippingJiao Yang, Cheng-Di Weng, Han-Min Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2024
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Science Progress|March 19, 2025
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of <i>EGFR</i> exon 20: A retrospective analysisKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Journal of International Medical Research|December 16, 2025
Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulationKe-Jun Liu, Tao Jiang, Quan-Quan Tan, et al.
Cancer Medicine|February 4, 2026
Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 RearrangementQuan-Quan Tan, Yu-Qing Chen, Yu-Er Gao, et al.
Cancer Treatment and Research Communications|April 30, 2023
Pathological characteristics and tumour immune microenvironment of lung malignancies with RET rearrangementQing-Yun Gao, Fa-Man Xiao, Xiao-Cheng Lin, et al.
Discover Oncology|May 27, 2026
Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skippingJiao Yang, Cheng-Di Weng, Han-Min Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2024
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Science Progress|March 19, 2025
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of <i>EGFR</i> exon 20: A retrospective analysisKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Pageof 1